Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34327214&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline #MMPMID34327214
Lau EY; Negrete OA; Bennett WFD; Bennion BJ; Borucki M; Bourguet F; Epstein A; Franco M; Harmon B; He S; Jones D; Kim H; Kirshner D; Lao V; Lo J; McLoughlin K; Mosesso R; Murugesh DK; Saada EA; Segelke B; Stefan MA; Stevenson GA; Torres MW; Weilhammer DR; Wong S; Yang Y; Zemla A; Zhang X; Zhu F; Allen JE; Lightstone FC
Front Mol Biosci 2021[]; 8 (?): 678701 PMID34327214show ga
A rapid response is necessary to contain emergent biological outbreaks before they can become pandemics. The novel coronavirus (SARS-CoV-2) that causes COVID-19 was first reported in December of 2019 in Wuhan, China and reached most corners of the globe in less than two months. In just over a year since the initial infections, COVID-19 infected almost 100 million people worldwide. Although similar to SARS-CoV and MERS-CoV, SARS-CoV-2 has resisted treatments that are effective against other coronaviruses. Crystal structures of two SARS-CoV-2 proteins, spike protein and main protease, have been reported and can serve as targets for studies in neutralizing this threat. We have employed molecular docking, molecular dynamics simulations, and machine learning to identify from a library of 26 million molecules possible candidate compounds that may attenuate or neutralize the effects of this virus. The viability of selected candidate compounds against SARS-CoV-2 was determined experimentally by biolayer interferometry and FRET-based activity protein assays along with virus-based assays. In the pseudovirus assay, imatinib and lapatinib had IC(50) values below 10 muM, while candesartan cilexetil had an IC(50) value of approximately 67 microM against M(pro) in a FRET-based activity assay. Comparatively, candesartan cilexetil had the highest selectivity index of all compounds tested as its half-maximal cytotoxicity concentration 50 (CC(50)) value was the only one greater than the limit of the assay (>100 muM).
free
free
free
Front+Mol+Biosci 2021 ; 8 (?): 678701
